S P O Jansson1, K Fall2,3, O Brus2, A Magnuson2, P Wändell4, C J Östgren5, O Rolandsson6. 1. Family Medicine Research Centre, Örebro County Council, School of Health and Medical Sciences, Örebro University, Örebro, Sweden. 2. Clinical Epidemiology and Biostatistics, Faculty of Medicine and Health, Örebro University, Örebro, Sweden. 3. School of Health and Medical Sciences, Örebro University, Örebro, Sweden. 4. Department of Neurobiology, Care Sciences and Society, Unit of Family Medicine, Karolinska Institutet, Huddinge, Sweden. 5. Division of Community Medicine, Department of Medicine and Health Sciences, Faculty of Health Sciences, Linköping University, Department of Local Care West, County Council of Östergötland, Linköping, Sweden. 6. Department of Public Health and Clinical Medicine, Family Medicine, Umeå University, Umeå, Sweden.
Abstract
AIM: To investigate the changes in prevalence and incidence of pharmacologically and non-pharmacologically treated diabetes in Sweden during 2005 to 2013. METHODS: We obtained data on gender, date of birth and pharmacologically and non-pharmacologically treated diabetes from national registers for all Swedish residents. RESULTS: During the study period a total of 240 871 new cases of pharmacologically treated diabetes was found. The age-standardized incidence during the follow-up was 4.34 and 3.16 per 1000 individuals in men and women, respectively. A decreasing time trend in incidence for men of 0.6% per year (0.994, 95% CI 0.989-0.999) and for women of 0.7% per year (0.993, 95% CI 0.986-0.999) was observed. The age-standardized prevalence increased from 41.9 and 29.9 per 1000 in 2005/2006 to 50.8 and 34.6 in 2012/2013 in men and women, respectively. This corresponds to an annually increasing time trend for both men (1.024, 95% CI 1.022-1.027) and women (1.019, 95% CI 1.016-1.021). The total age-standardized prevalence of pharmacologically and non-pharmacologically treated diabetes (2012) was 46.9 per 1000 (55.6 for men and 38.8 for women). This corresponds to an annually increasing time trend (2010-2012) for both men (1.017, 95% CI 1.013-1.021) and women (1.012, 95% CI 1.008-1.016). CONCLUSIONS: The prevalence of pharmacologically treated diabetes increased moderately during 8 years of follow-up, while the incidence decreased modestly. This is in contrast to the results reported by most other studies. The total prevalence of diabetes (both pharmacologically and non-pharmacologically treated) in Sweden is relatively low, from a global viewpoint.
AIM: To investigate the changes in prevalence and incidence of pharmacologically and non-pharmacologically treated diabetes in Sweden during 2005 to 2013. METHODS: We obtained data on gender, date of birth and pharmacologically and non-pharmacologically treated diabetes from national registers for all Swedish residents. RESULTS: During the study period a total of 240 871 new cases of pharmacologically treated diabetes was found. The age-standardized incidence during the follow-up was 4.34 and 3.16 per 1000 individuals in men and women, respectively. A decreasing time trend in incidence for men of 0.6% per year (0.994, 95% CI 0.989-0.999) and for women of 0.7% per year (0.993, 95% CI 0.986-0.999) was observed. The age-standardized prevalence increased from 41.9 and 29.9 per 1000 in 2005/2006 to 50.8 and 34.6 in 2012/2013 in men and women, respectively. This corresponds to an annually increasing time trend for both men (1.024, 95% CI 1.022-1.027) and women (1.019, 95% CI 1.016-1.021). The total age-standardized prevalence of pharmacologically and non-pharmacologically treated diabetes (2012) was 46.9 per 1000 (55.6 for men and 38.8 for women). This corresponds to an annually increasing time trend (2010-2012) for both men (1.017, 95% CI 1.013-1.021) and women (1.012, 95% CI 1.008-1.016). CONCLUSIONS: The prevalence of pharmacologically treated diabetes increased moderately during 8 years of follow-up, while the incidence decreased modestly. This is in contrast to the results reported by most other studies. The total prevalence of diabetes (both pharmacologically and non-pharmacologically treated) in Sweden is relatively low, from a global viewpoint.
Authors: Anna Norhammar; Johan Bodegård; Thomas Nyström; Marcus Thuresson; Jan W Eriksson; David Nathanson Journal: Diabetologia Date: 2016-05-18 Impact factor: 10.122
Authors: Johan Nilsson Sommar; Christer Johansson; Boel Lövenheim; Peter Schantz; Anders Markstedt; Magnus Strömgren; Helena Stigson; Bertil Forsberg Journal: Scand J Public Health Date: 2021-05-12 Impact factor: 3.199
Authors: Sun Ok Song; Yong Ho Lee; Dong Wook Kim; Young Duk Song; Joo Young Nam; Kyoung Hye Park; Dae Jung Kim; Seok Won Park; Hyun Chul Lee; Byung Wan Lee Journal: Endocrinol Metab (Seoul) Date: 2016-06-10
Authors: Sander de Kort; Ad A M Masclee; Silvia Sanduleanu; Matty P Weijenberg; Myrthe P P van Herk-Sukel; Nico J J Oldenhof; Joop P W van den Bergh; Harm R Haak; Maryska L Janssen-Heijnen Journal: Sci Rep Date: 2017-04-24 Impact factor: 4.379
Authors: Ali Naseribafrouei; Bent-Martin Eliassen; Marita Melhus; Ann Ragnhild Broderstad Journal: Int J Circumpolar Health Date: 2016-08-08 Impact factor: 1.228
Authors: Stephanie H Read; Joannes J Kerssens; David A McAllister; Helen M Colhoun; Colin M Fischbacher; Robert S Lindsay; Rory J McCrimmon; John A McKnight; John R Petrie; Naveed Sattar; Sarah H Wild Journal: Diabetologia Date: 2016-07-28 Impact factor: 10.122